Please assess the completion status of the following clinical trial:

Trial Title: Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria~1. Male and female subjects who are 18 years of age to less than 65 years of age.~2. Meets criteria for moderate to severe opioid use disorder as per Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria and confirmed by the Mini International Neuropsychiatric Interview (MINI) with physiological dependence as evidenced by a Clinical Opiate Withdrawal (COWS) score of \>5 or a positive naloxone challenge upon admission on Day 1.~3. Subjects who can read, understand, and provide written informed consent. Women of childbearing potential must have a negative pregnancy test and agree to be abstinent or use an acceptable method of contraception for the duration of the study.~Exclusion Criteria~1. Positive urine pregnancy test at screening or when tested or currently breast feeding.~2. Clinically significant history of cardiac disease, screening and baseline heart rate of \<55 beats per minutes or systolic blood pressure \<110 mmHg or diastolic blood pressure \<70 mmHg.~3. History or presence of a significant medical disease or disorder which, in the opinion of the investigator, increases the risk or may confound the interpretation of study measures, as confirmed by screening laboratory results.~4. Hepatic dysfunction (marked by ascites, or bilirubin \>10% above the upper limit of normal \[ULN\] or liver function tests \>3 x ULN) at the screening visit.~5. Acute active Hepatitis B or C as evidenced by positive serology and aspartate aminotransferase (AST)/alanine aminotransferase (ALT) \>2 x ULN.~6. Clinically significant abnormal ECG findings such as second- or third-degree heart block, uncontrolled arrhythmia, or QTcF (Fridericia correction formula) interval \>450 msec for males, and \>470 msec for females at screening or prior to dosing.~7. Any psychiatric disorder that would compromise ability to complete study requirements.~8. Currently meets DSM-5 criteria for substance abuse disorder, moderate or severe for any substance other than opioids, caffeine, or nicotine and/or current physical dependence on drugs that pose risk of withdrawal that requires medical management such as alcohol or benzodiazepines.~9. History of suicidal behavior within the last 1 year prior to screening.~10. Participation in a clinical trial of a non-FDA-approved pharmacological agent within 30 days prior to screening.~11. Use of any excluded medication at screening or anticipated/required use during the study period.~12. Subjects with a history of intolerance to morphine.~13. Any finding that, in the view of the principal investigator, would compromise the subject's ability to fulfill the protocol visit schedule or visit requirements.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1- Dexmedetomidine (30 Micrograms) vs. Placebo (Type: EXPERIMENTAL): Sublingual film containing 30 Micrograms Dexmedetomidine or Placebo Sublingual film
- Cohort 2- Dexmedetomidine (60 Micrograms) vs. Placebo (Type: EXPERIMENTAL): Sublingual film containing 60 Micrograms Dexmedetomidine or Placebo Sublingual film
- Cohort 3- Dexmedetomidine (90 Micrograms) vs. Placebo (Type: EXPERIMENTAL): Sublingual film containing 90 Micrograms Dexmedetomidine or Placebo Sublingual film
- Cohort 4- Dexmedetomidine (120 Micrograms) vs. Placebo (Type: EXPERIMENTAL): Sublingual film containing 120 Micrograms Dexmedetomidine or Placebo Sublingual film
- Cohort 5- Dexmedetomidine (180 Micrograms) vs. Placebo (Type: EXPERIMENTAL): Sublingual film containing 180 Micrograms Dexmedetomidine or Placebo Sublingual film
- Cohort 6- Dexmedetomidine (240 Micrograms) vs. Placebo (Type: EXPERIMENTAL): Sublingual film containing 240 Micrograms Dexmedetomidine or Placebo Sublingual film

Based on this trial design, predict the completion outcome and termination type (if applicable).